Post-approval studies (Phase 4)Study completedNCT01222403
What this trial is testing
A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older
Who this might be right for
Influenza
Novartis Vaccines 767